Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) EBT Margin (2022 - 2025)

Arcutis Biotherapeutics (ARQT) has 4 years of EBT Margin data on record, last reported at 13.59% in Q4 2025.

  • For Q4 2025, EBT Margin rose 2867.0% year-over-year to 13.59%; the TTM value through Dec 2025 reached 3.98%, up 7972.0%, while the annual FY2025 figure was 3.98%, 7972.0% up from the prior year.
  • EBT Margin reached 13.59% in Q4 2025 per ARQT's latest filing, up from 7.55% in the prior quarter.
  • Across five years, EBT Margin topped out at 13.59% in Q4 2025 and bottomed at 15123.72% in Q3 2022.
  • Average EBT Margin over 4 years is 1645.02%, with a median of 150.84% recorded in 2023.
  • Peak YoY movement for EBT Margin: skyrocketed 1498458bps in 2023, then skyrocketed 2867bps in 2025.
  • A 4-year view of EBT Margin shows it stood at 2432.25% in 2022, then surged by 80bps to 489.86% in 2023, then surged by 97bps to 15.09% in 2024, then skyrocketed by 190bps to 13.59% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 13.59% in Q4 2025, 7.55% in Q3 2025, and 19.07% in Q2 2025.